Morgan Todd M, Lange Paul H, Porter Michael P, Lin Daniel W, Ellis William J, Gallaher Ian S, Vessella Robert L
Department of Urology, University of Washington School of Medicine, 1959 NE Pacific, BB-1115, Box 356510, Seattle, WA 98195, USA.
Clin Cancer Res. 2009 Jan 15;15(2):677-83. doi: 10.1158/1078-0432.CCR-08-1754.
Men with apparently localized prostate cancer often relapse years after radical prostatectomy. We sought to determine if epithelial-like cells identified from bone marrow in patients after radical prostatectomy, commonly called disseminated tumor cells (DTC), were associated with biochemical recurrence.
We obtained bone marrow aspirates from 569 men prior to radical prostatectomy and from 34 healthy men with prostate-specific antigens <2.5 ng/mL to establish a comparison group. Additionally, an analytic cohort consisting of 98 patients with no evidence of disease (NED) after radical prostatectomy was established to evaluate the relationship between DTC and biochemical recurrence. Epithelial cells in the bone marrow were detected by magnetic bead enrichment with antibodies to CD45 and CD61 (negative selection) followed by antibodies to human epithelial antigen (positive selection) and confirmation with FITC-labeled anti-BerEP4 antibody.
DTC were present in 72% (408 of 569) of patients prior to radical prostatectomy. There was no correlation with pathologic stage, Gleason grade, or preoperative prostate-specific antigens. Three of 34 controls (8.8%) had DTC present. In patients with NED after radical prostatectomy, DTC were present in 56 of 98 (57%). DTC were detected in 12 of 14 (86%) NED patients after radical prostatectomy who subsequently suffered biochemical recurrence. The presence of DTC in NED patients was an independent predictor of recurrence (hazard ratio 6.9; 95% confidence interval, 1.03-45.9).
Approximately 70% of men undergoing radical prostatectomy had DTC detected in their bone marrow prior to surgery, suggesting that these cells escape early in the disease. Although preoperative DTC status does not correlate with pathologic risk factors, persistence of DTC after radical prostatectomy in NED patients was an independent predictor of recurrence.
患有明显局限性前列腺癌的男性在根治性前列腺切除术后数年常出现复发。我们试图确定根治性前列腺切除术后患者骨髓中鉴定出的上皮样细胞(通常称为播散肿瘤细胞,DTC)是否与生化复发相关。
我们在根治性前列腺切除术前行骨髓穿刺,从569名男性患者以及34名前列腺特异性抗原<2.5 ng/mL的健康男性中获取骨髓样本以建立对照组。此外,建立了一个由98名根治性前列腺切除术后无疾病证据(NED)的患者组成的分析队列,以评估DTC与生化复发之间的关系。通过使用抗CD45和CD61抗体进行磁珠富集(阴性选择),随后使用抗人上皮抗原抗体(阳性选择)检测骨髓中的上皮细胞,并用异硫氰酸荧光素标记的抗BerEP4抗体进行确认。
根治性前列腺切除术前,72%(569例中的408例)的患者存在DTC。这与病理分期、Gleason分级或术前前列腺特异性抗原均无相关性。34名对照组中有3名(8.8%)存在DTC。在根治性前列腺切除术后处于NED状态的患者中,98例中有56例(57%)存在DTC。在根治性前列腺切除术后处于NED状态且随后发生生化复发的14例患者中,有12例(86%)检测到DTC。NED患者中DTC的存在是复发的独立预测因素(风险比6.9;95%置信区间,1.03 - 45.9)。
约70%接受根治性前列腺切除术的男性在手术前骨髓中检测到DTC,这表明这些细胞在疾病早期就已逃逸。虽然术前DTC状态与病理风险因素无关,但根治性前列腺切除术后NED患者中DTC的持续存在是复发的独立预测因素。